Intelligence Profile
Science
AADvac1 is an active immunotherapy targeting pathological tau protein in Alzheimer's disease. It is designed to stimulate the body's immune system to produce antibodies against the abnormal tau protein, which is implicated in neurodegenerative processes.
Mechanism of Action:
Tau Protein Targeting: AADvac1 focuses on the tau protein, specifically targeting its pathological forms. The accumulation and misfolding of tau proteins in neurons lead to the formation of neurofibrillary tangles, a hallmark of Alzheimer's disease.
Induction of Antibodies: The vaccine encourages the body to produce antibodies against the pathological tau protein. By binding to the tau proteins, these antibodies facilitate their clearance from the brain.
Reduction of Tau Pathology: Through active immunization, AADvac1 aims to reduce tau aggregation, thereby potentially slowing the progression of neurodegeneration.
Immune Response: The vaccine induces a specific immune response without causing significant adverse effects, making it a promising candidate for treating tauopathies in Alzheimer's patients.
Clinical studies and systematic reviews (PMID: 40820539, 38101301, 39580468) highlight the safety, tolerability, and immunogenic potential of AADvac1, noting its capability to reduce markers associated with Alzheimer's disease pathology in clinical settings.
Disclaimer:
This information is intended for educational purposes and is not a substitute for professional medical advice. Always seek the advice of your healthcare provider with any questions regarding a medical condition.